Abstract
The deficiency of conventional drugs that are used in inflammatory rheumatic diseases are not able to prevent from progression of diseases have resulted in the development of new drugs, such as TUMOR Necrosis Factor-α (TNF-α) blocking agents, Interleukin-1 (IL-1) receptor antagonist and Anti-B cell (CD20) antibody. Biologic agents are a clear advancement in drug therapy. These newer agents have mechanisms of action targeted toward specific components of the immune system, which enable them to provide more reliable outcomes with fewer limiting side effects. They are administered subcutaneously and/or intravenously. The goal of the biologic treatment is to slow or block specific components of the immune system and halt tissue destruction.
Keywords: Biologic agents, pharmacokinetic, TNF-α blocking agents, IL-1 receptor antagonist, anti-B cell antibody, T-cell activator, IL-6 inhibitor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Pharmacokinetics of Biologic Agents
Volume: 9 Issue: 1
Author(s): Turhan Dost
Affiliation:
Keywords: Biologic agents, pharmacokinetic, TNF-α blocking agents, IL-1 receptor antagonist, anti-B cell antibody, T-cell activator, IL-6 inhibitor
Abstract: The deficiency of conventional drugs that are used in inflammatory rheumatic diseases are not able to prevent from progression of diseases have resulted in the development of new drugs, such as TUMOR Necrosis Factor-α (TNF-α) blocking agents, Interleukin-1 (IL-1) receptor antagonist and Anti-B cell (CD20) antibody. Biologic agents are a clear advancement in drug therapy. These newer agents have mechanisms of action targeted toward specific components of the immune system, which enable them to provide more reliable outcomes with fewer limiting side effects. They are administered subcutaneously and/or intravenously. The goal of the biologic treatment is to slow or block specific components of the immune system and halt tissue destruction.
Export Options
About this article
Cite this article as:
Dost Turhan, The Pharmacokinetics of Biologic Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711700
DOI https://dx.doi.org/10.2174/187152310790711700 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Soluble 5'-Nucleotidases in the Conversion of Nucleotide Analogs: Metabolic and Therapeutic Aspects
Current Medicinal Chemistry Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Current Pharmaceutical Design Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Nontoxic-dose of Deguelin Induce NPMc+ AML Cell Differentiation by Selectively Targeting Mt NPM1/SIRT1 Instead of HDAC1/3
Current Cancer Drug Targets Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring
Current Proteomics Relaxin-Like Peptides in Neoplastic Lesions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Activation of LINE-1 Retrotransposon Increases the Risk of Epithelial-Mesenchymal Transition and Metastasis in Epithelial Cancer
Current Molecular Medicine Random Mutagenesis Methods for In Vitro Directed Enzyme Evolution
Current Protein & Peptide Science Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Current Signal Transduction Therapy Organic Synthesis of C-Prenylated Phenolic Compounds
Current Organic Chemistry Advances in Mitotic Inhibitors for Cancer Treatment
Mini-Reviews in Medicinal Chemistry CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Current Pharmaceutical Design